A recent study compared a needle-free intranasal glucagon against standard intramuscular glucagon for the treatment of hypoglycemia in adults with type 1 diabetes.
The American Heart Association has released a new scientific statement reviewing the gender differences present in type 2 diabetes and how they affect risk of cardiovascular events.